CINV still occurs despite established antiemetic treatment

~50% of patients experience a CINV event despite use of guideline-recommended antiemetic regimens1

Learn about 5-day efficacy

Data from a prospective observational study where 742 patients received guideline-adherent antiemetic treatment for single-day HEC or MEC at 4 oncology practice networks, all using EMR systems, in Georgia, Tennessee, and Florida.1

  • CINV event defined as emesis or clinically significant nausea on days 1-5.
  • Up to 50% of patients at 4 different community oncology practice networks across the US (n=742) still experienced a CINV event despite the use of guideline-recommended CINV regimens1
    • The guideline-recommended HEC regimen included a 5-HT3 RA + NK1 RA + dexamethasone; the MEC regimen included a 5-HT3 RA + dexamethasone1
    • 5-HT3 RA used: palonosetron (94%) or ondansetron (5%)1

Early control of CINV is important for future efficacy2

  • Patients with uncontrolled CINV at cycle 1 had 4 times the rate of anticipatory CINV prior to cycle 23
  • Antiemetics that provide broad coverage of acute and delayed CINV with proven efficacy should be preferred4

The high rates of CINV reveal the need for further improvements in 5-HT3 RAs

5-HT3 RA=5-hydroxytryptamine receptor antagonist; CINV=chemotherapy-induced nausea and vomiting; HEC=highly emetogenic chemotherapy; MEC=moderately emetogenic chemotherapy; NK1 RA=neurokinin 1 receptor antagonist.

References:

  1. Gilmore et al. J Oncol Pract. 2014.
  2. Schwartzberg et al. Am Health Drug Benefits. 2015.
  3. Aapro et al. Ann Oncol. 2006.
  4. Rapoport. Front Pharmacol. 2017.
  5. SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.